Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2006-8-21
pubmed:abstractText
The activating BRAF(V600E) mutation is the most common genetic alteration reported in papillary thyroid carcinoma (PTC). While some reports suggest the BRAF(V600E) mutation is associated with factors predicting a poor prognosis and recurrence, this remains a controversial issue.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
0300-0664
pubmed:author
pubmed:issnType
Print
pubmed:volume
65
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
364-8
pubmed:dateRevised
2009-11-19
pubmed:meshHeading
pubmed-meshheading:16918957-Adult, pubmed-meshheading:16918957-Carcinoma, Papillary, pubmed-meshheading:16918957-Female, pubmed-meshheading:16918957-Fluorodeoxyglucose F18, pubmed-meshheading:16918957-Follow-Up Studies, pubmed-meshheading:16918957-Humans, pubmed-meshheading:16918957-Iodine Radioisotopes, pubmed-meshheading:16918957-Male, pubmed-meshheading:16918957-Middle Aged, pubmed-meshheading:16918957-Multivariate Analysis, pubmed-meshheading:16918957-Neoplasm Recurrence, Local, pubmed-meshheading:16918957-Point Mutation, pubmed-meshheading:16918957-Positron-Emission Tomography, pubmed-meshheading:16918957-Prognosis, pubmed-meshheading:16918957-Proportional Hazards Models, pubmed-meshheading:16918957-Proto-Oncogene Proteins B-raf, pubmed-meshheading:16918957-Radiopharmaceuticals, pubmed-meshheading:16918957-Survival Analysis, pubmed-meshheading:16918957-Thyroid Neoplasms, pubmed-meshheading:16918957-Thyroidectomy
pubmed:year
2006
pubmed:articleTitle
The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma.
pubmed:affiliation
Department of Internal Medicine, Asan Medical Centre, University of Ulsan College of Medicine, Seoul, Korea.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't